A Second-Line Treatment Option for Hepatocellular Carcinoma

Article Type
Changed
Fri, 07/26/2024 - 10:53

In this special supplement to Federal Practitioner, Dr. Binu John of the University of Miami discusses the challenges and treatment options for Hepatocellular Carcinoma (HCC), a common type of liver cancer, with a focus on patients with Child-Pugh B cirrhosis. It highlights the increasing incidence of liver cancer, especially in the context of cirrhosis caused by various factors, and the significance of early diagnosis and curative treatment in improving survival rates.

 

Click here to Read More

 

 

 

 

 

Sponsor
Developed under the direction and sponsorship of Exelixis, Inc. This content wa…
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Exelixis, Inc. This content wa…
Sponsor
Developed under the direction and sponsorship of Exelixis, Inc. This content wa…

In this special supplement to Federal Practitioner, Dr. Binu John of the University of Miami discusses the challenges and treatment options for Hepatocellular Carcinoma (HCC), a common type of liver cancer, with a focus on patients with Child-Pugh B cirrhosis. It highlights the increasing incidence of liver cancer, especially in the context of cirrhosis caused by various factors, and the significance of early diagnosis and curative treatment in improving survival rates.

 

Click here to Read More

 

 

 

 

 

In this special supplement to Federal Practitioner, Dr. Binu John of the University of Miami discusses the challenges and treatment options for Hepatocellular Carcinoma (HCC), a common type of liver cancer, with a focus on patients with Child-Pugh B cirrhosis. It highlights the increasing incidence of liver cancer, especially in the context of cirrhosis caused by various factors, and the significance of early diagnosis and curative treatment in improving survival rates.

 

Click here to Read More

 

 

 

 

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored Supplement
Gate On Date
Thu, 08/31/2023 - 22:15
Un-Gate On Date
Thu, 08/31/2023 - 22:15
Use ProPublica
CFC Schedule Remove Status
Thu, 08/31/2023 - 22:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
386222.2
Product Name
Federal Practitioner Custom Print